CD19 CAR-T cells therapy (Kite Pharma)

N/A

Report date: 2025/12/12 17:41:49

Base Information

Drug NameCD19 CAR-T cells therapy (Kite Pharma)

Drug Alias NameCAR-transduced autologous T cells therapy (Kite Pharma)KITE-197

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesKite Pharma

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, Diffuse

Inactive IndicationsN/A

Other Information

ATC CodeN/A